⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplementary Figure 7 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Izuchukwu F. Okpalanwaka Elizabeth A. Daugherity Amanda L. McCormick Trevor S. Anderson Savanna L. Smith Caryn Lawrence Duke Appiah Devin B. Lowe

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Regorafenib in combination with a PD-L1/CD3 bispecific antibody enhances antitumor effects against colon cancer.
KEY EVIDENCE: CD8+ T cell exhaustion was notably increased following treatment with REG/bsAb therapy.
APPROACH: Analysis focused on immune response changes in colon cancer models after therapy.
SIGNIFICANCE: This combination therapy may improve treatment outcomes for patients with colon cancer.

Implication

Supplementary figure shows enhanced t cell exhaustion after regorafenib and bispecific antibody therapy in colon cancer.

Abstract

Supplementary Figure 7 demonstrates enhanced CD8+ T cell exhaustion after REG/bsAb therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okpalanwaka et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0236 https://doi.org/10.1158/1535-7163.29760629

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
2Supplementary Figure 3 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
3Supplementary Figure 9 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
4Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
5Supplementary Figure 4 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025

Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025